Anti-Henipavirus Monoclonal Antibodies with Broad Spectrum Neutralization
Summary
The USPTO granted Patent US12590141B2 to the Academy of Military Medical Science covering monoclonal antibodies targeting Henipavirus glycoprotein G. The patent claims antibodies combining macaque variable regions with human constant regions, demonstrating broad neutralization activity against Nipah and Hendra viruses. The patent includes 9 claims and covers encoding nucleic acids for therapeutic applications.
What changed
USPTO issued Patent US12590141B2 to the Academy of Military Medical Science, PLA, for anti-Henipavirus monoclonal antibodies with broad spectrum neutralization activity. The patent covers antibodies comprising macaque variable regions and human constant regions, with binding activity to both Nipah virus and Hendra virus glycoprotein G. The granted patent includes 9 claims covering the antibody compositions and encoding nucleic acids for treating Henipavirus diseases. Filing date was June 27, 2021, under Application No. 18005979.
This patent grant conveys intellectual property rights to the Academy of Military Medical Science. Pharmaceutical companies or researchers developing Henipavirus therapeutics should assess potential licensing needs or design-around considerations. No compliance deadlines or regulatory actions are triggered by this patent issuance.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Monoclonal antibodies against Henipavirus glycoprotein G and encoding nucleic acids thereof
Grant US12590141B2 Kind: B2 Mar 31, 2026
Assignee
Academy of Military Medical Science, PLA
Inventors
Wei Chen, Changming Yu, Yujiao Liu, Pengfei Fan, Guanying Zhang, Yaohui Li, Jianmin Li, Xiangyang Chi, Meng Hao, Ting Fang, Yunzhu Dong, Xiaohong Song, Yi Chen, Shuling Liu
Abstract
Provided is an anti-Henipavirus monoclonal antibody having broad spectrum neutralization activity, wherein the antibody comprises a macaque variable region and a human constant region. The antibody of the present invention has good binding activity to both Nipah virus glycoprotein G and Hendra virus glycoprotein G, can effectively neutralize Nipahpseudovirus and Hendra pseudovirus, and can be used for preparing drugs for treating Henipavirus diseases.
CPC Classifications
A61P 31/14 C07K 16/10 C07K 16/1027 C07K 2317/24 C07K 2317/33 C07K 2317/76 C07K 2317/92 C07K 2317/21 C07K 2317/52 C07K 2317/565
Filing Date
2021-06-27
Application No.
18005979
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.